Infant RSV Immunity Study
Recruiting now NCT07653347
Run by University of British Columbia · for Up to 6 Months months · All sexes · accepts healthy volunteers
What this study is about
Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (\>6-9 months) in infancy.
Who can join (things the study team will check)
Inclusion Criteria: Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital. Exclusion Criteria: Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \< 35 weeks of gestation, or with chronic medical conditions).…
Where this trial is running
- BC Women's Hospital and Health Centre, Vancouver, British Columbia, Canada
Who to contact
Pascal Lavoie, MDCM PhD FRCPC · 604-875-2135 · plavoie@bcchr.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07653347.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.